Disclosures: Maria Spencer Sandino: Nothing to Disclose, Laura Andrea Huidobro: Nothing to Disclose, Franco Godoy: Nothing to Disclose, Danilo Alvares: Nothing to Disclose, Juan Pablo Arab: Nothing to Disclose, Daniel Cabrera: Nothing to Disclose, Marco Arrese: Nothing to Disclose, Francisco Barrera: Nothing to Disclose, Catterina Ferreccio: Nothing to Disclose 1179 FORECASTED CHANGES IN TUMOR CHARACTERISTICS AND SURVIVAL OF PATIENTS WITH NONVIRAL HEPATOCELLULAR CARCINOMA IN THE UNITED STATES: A MODELING STUDY BASED ON THE SEER-MEDICARE DATABASE Joanne Liu 1 Nicholas Chien 1 Curtis Chong 2 Scott Barnett 1 Ramsey Cheung 1 Mindie Nguyen 1 , 1 Division of Gastroenterology and Hepatology, Dept of Medicine, Stanford University Medical Center, 2 Division of Oncology, Department of Medicine, Stanford University Medical Center Background: HCC incidence related to nonviral liver diseases is rising

Drug Interactions and Medication Safety with Tirzepatide Tirzepatide does not undergo hepatic metabolism, which reduces the likelihood of major cytochrome P450-mediated drug interactions common to many oral medications
Before you roll up your sleeve, heres what you need to know
Further studies have found that P53 can inhibit system Xc- uptake of cystine by downregulating the expression of SLC7A11, thereby affecting the activity of GPX4 and resulting in the reduction of antioxidant capacity, ROS accumulation, and ferroptosis 11